Oncology | Blood cancer
Nurturing advances in oncohematology
QIAGEN's oncohematology solutions bring innovation in molecular testing to patients, faster and without compromise. We support your path to personalized blood cancer care and advancements in molecular research with a comprehensive assay, platform and service portfolio – from Sample to Insight.
Contact an expert
Discover how QIAGEN can help you and your patients.
JAK2Sensitive detection and quantification of the JAK2 V617F mutation to aid diagnosis of MPN.
CALRImprove MPN diagnosis with easy and sensitive CALR mutation detection.
BCR-ABL1 MbcrHighly sensitive and reliable monitoring of IS-standardized molecular response to treatment in CML.
BCR-ABL1 mbcrSensitive quantification of BCR-ABL1 mbcr for monitoring minimal/measurable residual disease (MRD) Ph+ ALL.
PML-RARA bcr1Sensitive quantification of PML-RARA bcr1 for monitoring minimal/measurable residual disease in AML.
WT1Sensitive quantification of Wilm's tumor (WT1) gene transcripts for monitoring minimal/measurable residual disease in AML.
Explore the power of oneMaximize the information derived from a single total nucleic acid sample by simultaneously preparing DNA and RNA libraries in one consolidated workflow.
With the new QIAseq Multimodal Leukemia Panel, you can simultaneously detect RNA fusions, exon skipping events and gene expression levels, along with SNVs, InDels, CNVs profiles, in a single, one-day workflow from as little as 10 ng of sample.
Easily classify myeloid malignanciesQIAGEN Digital Insights clinical decision support software enables faster test turnaround times and higher confidence reporting for any indication on your sequencing platform.
QIAGEN Clinical Insight (QCI) Interpret provides transparent automation of blood cancer sub-classification and prognostic assessment, showing you how certain cancer subtypes potentially relate to therapeutic options.